Trial Profile
To evaluate the outcomes of Pemetrexed,Carboplatin and Bevacizumab followed by maintainence Pemetrexed and Bevacizumab in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Nov 2016 New trial record
- 01 Oct 2016 Results published in the Journal of Thoracic Oncology